Author

James Clubley

Observed name: J. Clubley

Institution: Immunocore (United Kingdom)

Observed institution: Immunocore (United Kingdom)

ORCID: 0009-0004-1823-4136

Observed ORCID: 0009-0004-1823-4136

OpenAlex ID: A5086758443

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

2025 · Esra Güç, Agatha Treveil, et al. · Nature Communications · 20

Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial

2026 · Linos Vandekerckhove, Julie Fox, et al. · Nature Communications · 5

959 Tebentafusp controls disease and prolongs survival by increasing the T cell: tumor cell ratio, activating T cells and inhibiting tumor proliferation in metastatic uveal melanoma patients

2025 · Adel Benlahrech, James Clubley, et al. · Journal for ImmunoTherapy of Cancer · 1

1021P Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC

2024 · L. Benlahrech, J. Clubley, et al. · Annals of Oncology

1108 Novel regulators of ImmTAC-mediated killing of melanoma cancer cells revealed by genome-wide CRISPR-Cas9 screens

2023 · Aleksandra Raczka, Sophie Khakoo, et al. · Journal for ImmunoTherapy of Cancer

2238P Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages

2023 · J.M. Piulats Rodriguez, E. Guc, et al. · Annals of Oncology

1692P ImmTAC redirect T cells against patient-derived tumour organoids and three-dimensional melanospheres: Effects augmented by type I interferons

2022 · P. Kirk, D. Gascoyne, et al. · Annals of Oncology

Works count: 7

Citation count: 26

H-index: 2

I10-index: 1